Interleukin-6 (IL-6) is a pro-inflammatory cytokine implicated in the immune pathology
of neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD). Satralizumab, a humanised
recycling monoclonal antibody that binds to the IL-6 receptor, reduced risk of relapse
in patients with NMO or NMOSD as add-on therapy in the SAkuraSky study (NCT02028884)
and monotherapy in the SAkuraStar study (NCT02073279).
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2019 Published by Elsevier Inc.
